These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 32864107)

  • 1. Case Report: Acute effect of benralizumab on asthma exacerbation without concomitant corticosteroid use.
    Nolasco S; Campisi R; Intravaia R; Porto M; Pelaia C; Crimi N; Crimi C
    F1000Res; 2020; 9():637. PubMed ID: 32864107
    [No Abstract]   [Full Text] [Related]  

  • 2. Seasonal variability of exacerbations of severe, uncontrolled eosinophilic asthma and clinical benefits of benralizumab.
    DuBuske L; Newbold P; Wu Y; Trudo F
    Allergy Asthma Proc; 2018 Sep; 39(5):345-349. PubMed ID: 30077185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ability of Serum IgE Concentration to Predict Exacerbation Risk and Benralizumab Efficacy for Patients with Severe Eosinophilic Asthma.
    Jackson DJ; Humbert M; Hirsch I; Newbold P; Garcia Gil E
    Adv Ther; 2020 Feb; 37(2):718-729. PubMed ID: 31836949
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma.
    Chipps BE; Newbold P; Hirsch I; Trudo F; Goldman M
    Ann Allergy Asthma Immunol; 2018 May; 120(5):504-511.e4. PubMed ID: 29409951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study.
    Numata T; Miyagawa H; Nishioka S; Okuda K; Utsumi H; Hashimoto M; Minagawa S; Ishikawa T; Hara H; Araya J; Kuwano K
    BMC Pulm Med; 2020 Aug; 20(1):207. PubMed ID: 32746787
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.
    FitzGerald JM; Bleecker ER; Nair P; Korn S; Ohta K; Lommatzsch M; Ferguson GT; Busse WW; Barker P; Sproule S; Gilmartin G; Werkström V; Aurivillius M; Goldman M;
    Lancet; 2016 Oct; 388(10056):2128-2141. PubMed ID: 27609406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Onset of effect and impact on health-related quality of life, exacerbation rate, lung function, and nasal polyposis symptoms for patients with severe eosinophilic asthma treated with benralizumab (ANDHI): a randomised, controlled, phase 3b trial.
    Harrison TW; Chanez P; Menzella F; Canonica GW; Louis R; Cosio BG; Lugogo NL; Mohan A; Burden A; McDermott L; Garcia Gil E; Zangrilli JG;
    Lancet Respir Med; 2021 Mar; 9(3):260-274. PubMed ID: 33357499
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma.
    Katsaounou P; Buhl R; Brusselle G; Pfister P; Martínez R; Wahn U; Bousquet J
    Respir Med; 2019 Apr; 150():51-62. PubMed ID: 30961951
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-life cost-effectiveness of benralizumab in patients with severe asthma.
    Padilla-Galo A; García-Ruiz AJ; Levy Abitbol RC; Olveira C; Rivas-Ruiz F; García-Agua Soler N; Pérez Morales M; Valencia Azcona B; Tortajada-Goitia B; Moya-Carmona I; Levy-Naon A
    Respir Res; 2021 May; 22(1):163. PubMed ID: 34044819
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting β
    Bleecker ER; FitzGerald JM; Chanez P; Papi A; Weinstein SF; Barker P; Sproule S; Gilmartin G; Aurivillius M; Werkström V; Goldman M;
    Lancet; 2016 Oct; 388(10056):2115-2127. PubMed ID: 27609408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Real-Life effects of benralizumab on exacerbation number and lung hyperinflation in atopic patients with severe eosinophilic asthma.
    Pelaia C; Busceti MT; Crimi C; Carpagnano GE; Lombardo N; Terracciano R; Vatrella A; Pelaia G
    Biomed Pharmacother; 2020 Sep; 129():110444. PubMed ID: 32593131
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ChAracterization of ItaliaN severe uncontrolled Asthmatic patieNts Key features when receiving Benralizumab in a real-life setting: the observational rEtrospective ANANKE study.
    Menzella F; Bargagli E; Aliani M; Bracciale P; Brussino L; Caiaffa MF; Caruso C; Centanni S; D'Amato M; Del Giacco S; De Michele F; Di Marco F; Pastorello EA; Pelaia G; Rogliani P; Romagnoli M; Schino P; Senna G; Vultaggio A; Simoni L; Ori A; Boarino S; Vitiello G; Altieri E; Canonica GW
    Respir Res; 2022 Feb; 23(1):36. PubMed ID: 35183167
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A case of allergic bronchopulmonary aspergillosis successfully treated with mepolizumab.
    Terashima T; Shinozaki T; Iwami E; Nakajima T; Matsuzaki T
    BMC Pulm Med; 2018 Mar; 18(1):53. PubMed ID: 29587693
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma.
    Kavanagh JE; Hearn AP; Dhariwal J; d'Ancona G; Douiri A; Roxas C; Fernandes M; Green L; Thomson L; Nanzer AM; Kent BD; Jackson DJ
    Chest; 2021 Feb; 159(2):496-506. PubMed ID: 32882249
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-life rapidity of benralizumab effects in patients with severe allergic eosinophilic asthma: Assessment of blood eosinophils, symptom control, lung function and oral corticosteroid intake after the first drug dose.
    Pelaia C; Busceti MT; Vatrella A; Rago GF; Crimi C; Terracciano R; Pelaia G
    Pulm Pharmacol Ther; 2019 Oct; 58():101830. PubMed ID: 31344472
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The association between blood eosinophil count and benralizumab efficacy for patients with severe, uncontrolled asthma: subanalyses of the Phase III SIROCCO and CALIMA studies.
    Goldman M; Hirsch I; Zangrilli JG; Newbold P; Xu X
    Curr Med Res Opin; 2017 Sep; 33(9):1605-1613. PubMed ID: 28644104
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-life experience with benralizumab during 6 months.
    Padilla-Galo A; Levy-Abitbol R; Olveira C; Valencia Azcona B; Pérez Morales M; Rivas-Ruiz F; Tortajada-Goitia B; Moya-Carmona I; Levy-Naon A
    BMC Pulm Med; 2020 Jun; 20(1):184. PubMed ID: 32600318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of benralizumab on asthma exacerbation-related medical healthcare resource utilization and medical costs: results from the ZEPHYR 2 study.
    Chung Y; Maselli DJ; Mu F; Cook EE; Yang D; Young JA; Betts KA; Genofre E; Carstens D
    J Med Econ; 2023; 26(1):954-962. PubMed ID: 37441729
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significant improvement in lung function and asthma control after benralizumab treatment for severe refractory eosinophilic asthma.
    Menzella F; Ruggiero P; Galeone C; Scelfo C; Bagnasco D; Facciolongo N
    Pulm Pharmacol Ther; 2020 Oct; 64():101966. PubMed ID: 33039666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study.
    Menzies-Gow A; Gurnell M; Heaney LG; Corren J; Bel EH; Maspero J; Harrison T; Jackson DJ; Price D; Lugogo N; Kreindler J; Burden A; de Giorgio-Miller A; Padilla K; Martin UJ; Garcia Gil E
    Lancet Respir Med; 2022 Jan; 10(1):47-58. PubMed ID: 34619104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.